Scale-Up and Manufacturing of Regenerative Medicine

Amber Scorah

When introducing a regenerative medicine cell based product to a commercial setting, there are a number of things to take into consideration to ensure a commercially viable and safe product for patient use. In this podcast, William Fodor, Director of Translational Sciences, Cell Therapy Group, gives some great insights into the commercial manufacturing scale-up process of cell therapies.


Have Your Say
Rate this feature and give us your feedback in the comments section below